

# Comparison of Three Drug Combinations for Raccoon Immobilization

Shylo R. Johnson, Christine K. Ellis, Chad K. Wickham, Molly R. Selleck, Pauline Nol, Amy T. Gilbert,

---

The information contained in this study is provided for educational and informational purposes only, and should not be construed as suggesting, implying, establishing or making claims in any manner or respect regarding the safety, efficacy or therapeutic benefit of any of Wedgewood's compounded drug preparations. Any such claims can only be made with respect to drugs that have been tested in accordance with studies and labels approved by the United States Food and Drug Administration. Wedgewood is a compounding pharmacy whose preparations, by law, are not required to go through FDA's new drug approval process and, therefore, have not been tested for safety and efficacy. Wedgewood does not and should not be construed to make any safety, efficacy or other health claims about its compounded drug preparations and any implication to the contrary is specifically disavowed.

The information contained in this study is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a practitioner with any questions you may have regarding a medical condition or the medications used to treat it.

## Comparison of Three Drug Combinations for Raccoon Immobilization

**Shylo R. Johnson**, USDA, Wildlife Services, National Wildlife Research Center, Fort Collins, CO

**Christine K. Ellis**, USDA, Wildlife Services, National Wildlife Research Center, Fort Collins, CO

**Chad K. Wickham**, USDA, Wildlife Services, National Wildlife Research Center, Fort Collins, CO

**Molly R. Selleck**, USDA, Wildlife Services, National Wildlife Research Center, Fort Collins, CO

**Pauline Nol**, USDA, Veterinary Services, Centers for Epidemiology and Animal Health, Fort Collins, CO

**Amy T. Gilbert**, USDA, Wildlife Services, National Wildlife Research Center, Fort Collins, CO

**ABSTRACT:** Raccoons (*Procyon lotor*) are regularly handled for damage management and research objectives. Safe handling of these animals in the field requires drug combinations that provide effective and predictable results with high safety margins for both the animal and personnel handling the animal, but also have a low probability of abuse. United States Drug Enforcement Administration scheduling relates to the probability of a drug being abused; class I drugs are associated with the greatest potential for abuse. We compared three drug combinations: butorphanol-azaperone-medetomidine (BAM; class IV), nalbuphine-azaperone-medetomidine (NAM; unscheduled), and ketamine-xylazine (KX; class III). Through a dose titration process, we identified optimal drug dosages of 0.016 ml/kg for BAM, 0.018 ml/kg for NAM, and 0.096 ml/kg for KX. The induction time was similar for all drugs. Only with KX were raccoons able to recover unaided by reversal drugs. After giving reversals, recovery times for BAM and NAM were relatively quick (average < 7 minutes). Based on blood oxygen saturation levels and respiratory rate, oxygen was administered to 72%, 71%, and 21% of the raccoons immobilized with BAM, NAM, and KX, respectively. Breathing was cyclic in raccoons immobilized with BAM and NAM, and some raccoons were given reversal agents prior to completing a workup due to low respiratory rate or low oxygen saturation levels. Raccoons immobilized with KX were observed with a more regular breathing pattern. Based on our results, it is highly recommended that both oxygen and associated reversals be available when using BAM or NAM to immobilize raccoons.